Polydatin Attenuates Cisplatin‐Induced Acute Kidney Injury by Inhibiting Ferroptosis

Cisplatin is widely used in the treatment of solid tumors, but its application is greatly limited due to its nephrotoxicity; thus, there is still no effective medicine for the treatment of cisplatin‐induced acute kidney injury (Cis‐AKI). We previously identified that polydatin (PD) exerts nephroprotective effects by antioxidative stress in AKI models. Recent evidence suggests that oxidative stress‐induced molecular events overlap with the process of ferroptosis and that there are common molecular targets, such as glutathione (GSH) depletion and lipid peroxidation. Nevertheless, whether the nephroprotective effect of PD is related to anti‐ferroptosis remains unclear. In this study, the inhibitory effect of PD on ferroptosis was observed in both cisplatin‐treated HK‐2 cells (20 μ M) in vitro and a Cis‐AKI mouse model (20 mg/kg, intraperitoneally) in vivo, characterized by the reversion of excessive intracellular free iron accumulation and reactive oxygen species (ROS) generation, a decrease in malondialdehyde (MDA) content and GSH depletion, and an increase in glutathione peroxidase‐4 (GPx4) activity. Remarkably, PD dose‐dependently alleviated cell death induced by the system Xc − inhibitor erastin (10 μ M), and the effect of the 40 μ M dose of PD was more obvious than that of ferrostatin‐1 (1 μ M) and deferoxamine (DFO, 100 μ M), classical ferroptosis inhibitors. Our results provide insight into nephroprotection with PD in Cis‐AKI by inhibiting ferroptosis via maintenance of the system Xc − ‐GSH‐GPx4 axis and iron metabolism.